drug
(cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate)
Marketedupdated 5mo agoby $GILD GILEAD SCIENCES, INC.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 26, 2026
24 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (14)
- Apr 6, 2033patentUS 10039718*PED
- Oct 6, 2032formulationUS 10039718
- Oct 30, 2030patentUS 8633219*PED4.1y
- Apr 30, 2030formulationUS 86332193.6y
- Mar 3, 2030patentUS 8148374*PED3.4y
- Mar 3, 2030patentUS 9891239*PED3.4y
- Sep 3, 2029compositionUS 81483742.9y
- Sep 3, 2029formulationUS 98912392.9y
- Apr 26, 2027patentUS 7635704*PED206d
- Apr 26, 2027patentUS 8981103*PED206d
- Feb 27, 2027patentUS 7176220*PED148d
- Oct 26, 2026compositionUS 763570424d
- Oct 26, 2026compositionUS 898110324d
- Aug 27, 2026compositionUS 7176220
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 6h ago
Found something off?
comments(0)
5-min edit window · permanent after that